CervoMed says Phase 2a nfvPPA biomarker data will be presented at ISFTD 2026
CervoMed said initial 12-week biomarker results from its Phase 2a nfvPPA trial will be presented as a late-breaking oral session at ISFTD 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.